SEBOSTASE EXTREME DRY SKIN CREAM is introduced in the pharmaceutical technical file as a pharma-grade API, with the model/type recorded as SEBOSTASE EXTREME DRY SKIN CREAM pharma-grade API for tablet, capsule, granule, injection, oral, and injectable use. The trade name contains the phrase “extreme dry skin cream,” but the material is not a finished cosmetic or non-sterile emollient; it is released as an active raw material under ICH Q7 conditions with a multi-route Certificate of Analysis. No preservative, fragrance, or emulsified water is present at release; such functional excipients are added only in downstream drug-product manufacturing. The specification framework is route-dependent because the same active entity may enter a direct compression blend for tablets, a granulated intermediate for hard gelatin capsules, or a sterile filtered solution for parenteral administration. The material is controlled for residual solvents under ICH Q3C, elemental impurities under ICH Q3D, and microbial quality under Ph. Eur. 2.6.12 or USP <61> for non-sterile use; injectable use additionally requires sterility and pyrogen controls. Because the route changes release parameters, the regulatory dossier must define separate acceptance criteria for solid oral and injectable presentations rather than rely on a single cosmetic-grade profile.

In tablet and capsule manufacture, the API is typically screened through an 850 µm or 425 µm aperture sieve to break agglomerates before blending. Because the material is designated for dry-skin applications, its lipid-affine character can reduce bulk density and increase adhesion to stainless-steel contact surfaces. A hydrophobic lubricant such as sodium stearyl fumarate or magnesium stearate is introduced at 0.5–1.0% w/w only after dissolution and content uniformity data are reviewed. Direct compression blends are mixed in a bin blender at 10–12 rpm for 15–20 min; if powder flow is inadequate, wet granulation in a high-shear granulator is used. For a 25 L bowl, screening settings of 200–300 min⁻¹ impeller speed and 1500–2000 min⁻¹ chopper speed are typical, but the endpoint is determined by torque or power consumption rather than fixed time. The resulting granulate is dried in a fluid-bed dryer with inlet air temperature 60–70 °C until loss on drying reaches the registered target. These are platform ranges, not validated parameters for this specific API.

Which batch-release parameters are non-negotiable across all routes?

For any route, batch release includes identification by Ph. Eur. 2.2.24 infrared absorption spectrophotometry or USP <197>, assay by USP <621> HPLC-UV, related substances by gradient reversed-phase HPLC, water content by USP <921> Karl Fischer titration, residue on ignition, residual solvents by USP <467>, and elemental impurities by USP <232> and USP <233>. Assay acceptance criteria are generally set at 98.0–102.0% on the dried basis for a monographed API; the registered value for this product must be taken from the approved specification. Water content is often submitted at ≤ 0.5% w/w for non-aqueous powder intermediates, but if the development report demonstrates a hydrate form with critical water activity, the limit is adjusted using dynamic vapour sorption data and the ICH Q6A decision tree. Residual solvents are limited by the most restrictive route; a Class 2 solvent under ICH Q3C has a permitted daily exposure value that must not be exceeded when the same material is used in an injectable product. Published batch data for this specific trade designation are limited; therefore, values in Table 1 are expressed as dossier-defined targets rather than standalone release limits.

For solid oral dosage forms, particle-size distribution is a primary determinant of blend uniformity, dissolution, and tablet tensile strength. The API is characterised by laser diffraction under ISO 13320:2020 or dynamic image analysis under ISO 13322-2, with limits for D10, D50, and D90 fixed during development. In direct compression, the screened API is blended with pre-sieved microcrystalline cellulose and co-processed lactose in a bin blender at 10–12 rpm for 15–20 min; if the angle of repose exceeds 35° or Carr index exceeds 25, wet granulation is introduced. A 25 L high-shear granulator operating at 200–300 min⁻¹ impeller speed and 1500–2000 min⁻¹ chopper speed is used for screening; the endpoint is determined by torque or power consumption rather than fixed time. The granulate is dried in a fluid-bed dryer with inlet air temperature 60–70 °C until loss on drying reaches the registered value, then milled through a 1.0 mm screen before encapsulation or compression. These are platform-setting ranges, not validated parameters for this specific API because pile density may shift with residual moisture and particle morphology.

For capsules, the dried granulate is filled using an automatic capsule machine with pin settings adjusted for bulk density. The fill weight is controlled by tamping pins; if bulk density is below 0.45 g/mL, precompression or slugging may be required to increase density. For tablet compression, the granulate is compressed on a rotary press with a precompression force of 10–12 kN and main compression force of 20–30 kN for a standard 10 mm flat-faced bevel tooling; these values depend on the final tablet hardness target. The compressed tablets are assessed for friability by USP <1216> and disintegration by USP <701>; hardness is not a compendial release parameter but is monitored as process control. If capping or lamination occurs, the moisture content of the granulate is adjusted and the compression speed is reduced below 60 rpm. Capsule dissolution is evaluated with USP <711>; a Q value is established in the development report and is not inferred from the API’s cream-like designation.

When the API is transferred from a cream-like intermediate to a sterile injectable

At the point of technology transfer from a semi-solid-like intermediate to a sterile injectable, the formulation scientist must re-justify particle size, polymorphism, and residual solvent profile. A polymorphic form that is well tolerated in a tablet may exhibit different solubility and dissolution in an aqueous injectable vehicle; a form change can be detected by differential scanning calorimetry at heating rate 10 K/min and by X-ray powder diffraction using Cu Kα radiation. If the API shows low aqueous solubility, co-solvent or cyclodextrin complexation is required; biocompatibility of the selected cyclodextrin is then assessed under ICH M3(R2) and the relevant regional guidance. The prepared solution is clarified through a 0.45 µm prefilter followed by a 0.22 µm sterilizing-grade polyvinylidene fluoride or polyethersulfone filter; filter compatibility is confirmed by bubble point and product-specific bacterial retention under USP <71> and ASTM F838-20. The final container is Type I borosilicate glass with chlorobutyl stoppers; extractables and leachables are evaluated under USP <1664> and ICH Q3E where applicable. Batch records must document that the maximum holding time before sterile filtration does not exceed the validated bioburden control time, often 4 h for ambient processing; the specific holding time is established in process validation.

For oral solutions and suspensions, the API is dissolved or dispersed in a non-solvent vehicle after particle-size control. Viscosity of the final suspension is measured with a rotational viscometer at 25 °C and shear rate 50 s⁻¹; sedimentation volume is recorded at 24 h and 72 h using a 100 mL graduated cylinder. Preservative efficacy is confirmed by USP <51> or Ph. Eur. 5.1.3. This route may accept a wider particle-size range than injection, but the product must still meet microbial limits if not sterile. Published data for this specific configuration is limited; the formulation must be bracketed with experimental design rather than assumed from the cream-like designation.

Differences from cosmetic creams and ungraded API powders

A finished dry-skin cream is an emulsified dosage form with preservative, pH adjustment, and defined spreadability; the API described here is released without these functional additives. The pharma-grade powder is controlled for particle size, polymorphic purity, residual solvents, and elemental impurities, whereas a cosmetic cream is controlled primarily for microbial limits and emulsion stability. The difference from ordinary ungraded API powders is the multi-route specification: the material must be suitable for dry blending and for sterile filtration after appropriate processing. This dual-route capability imposes stricter limits on bioburden, pyrogens, and insoluble particulate burden than would be applied to an API intended only for topical use. When compared with unmodified powders of similar lipid affinity, the product may show higher adhesion to metal surfaces; batch records should therefore include cleaning verification for stainless-steel contact surfaces and a validated analytical method for residues. The absence of preservative at release also means that downstream aqueous preparations cannot rely on intrinsic preservation until the finished drug product is tested under USP <51> or Ph. Eur. 5.1.3.

Packaging is selected to minimise water vapour transmission and light exposure. The API is commonly filled into double polyethylene bags inside a fibreboard drum with desiccant when the registered water content limit is ≤ 0.5% w/w; for injectable use, the final container closure system may be a siliconized Type I glass vial with a fluoropolymer-coated stopper. The closure meets 21 CFR 211.94 and ISO 15378:2017. Retest dating is assigned from long-term stability chambers at 25 °C/60% RH and 30 °C/65% RH, with accelerated storage at 40 °C/75% RH for 6 months according to ICH Q1A. Operational boundaries include pre-drying at relative humidity above 60% if water content rises above the registered value; avoid direct contact with copper or brass equipment because elemental impurity transfer may occur. Incompatibilities with strongly alkaline excipients, amine-based additives, or peroxide-containing excipients should be evaluated under forced-degradation conditions because the dry-skin designation alone does not establish chemical compatibility.